James A Karlowsky

List of Publications by Year
in descending order

130 papers	5,480 citations	100601 38 h-index	104191 69 g-index
132 all docs	132 docs citations	132 times ranked	5140 citing authors

#	Article	IF	Citations
1	Absence of transmission of NDM and OXA-48 carbapenemase genes in a chronic care unit of a long-term care facility. Journal of Infection Prevention, 2022, 23, 15-19.	0.5	0
2	Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007â€“19. JAC-Antimicrobial Resistance, 2022, 4, dlab197.	0.9	10
3	Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019. International Journal of Antimicrobial Agents, 2022, 59, 106535.	1.1	22
4	PCV-15 and PPSV-23 coverage of invasive and respiratory tract Streptococcus pneumoniae, including MDR and XDR isolates: CANWARD 2007â€“20. Journal of Antimicrobial Chemotherapy, 2022, 77, 1444-1451.	1.3	2
5	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs, 2022, 82, 533-557.	4.9	12
6	Evaluation of the Hologic Aptima Combo 2 Assay for Detection of Neisseria gonorrhoeae from Joint Fluid Specimens. Journal of Clinical Microbiology, 2022, 60, e0253021.	1.8	1
7	Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. Journal of Global Antimicrobial Resistance, 2022, 30, 23-30.	0.9	6
8	Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018â€“20). JAC-Antimicrobial Resistance, 2022, 4, .	0.9	12
9	In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. Microbiology Spectrum, 2022, 10, .	1.2	9
10	Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115282.	0.8	7
11	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2021, 81, 233-256.	4.9	20
12	ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007â€“18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2815-2824.	1.3	8
13	Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007â€“18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2825-2832.	1.3	4
14	In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015â€“2018. Journal of Global Antimicrobial Resistance, 2021, 24, 249-256.	0.9	7
15	Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	17
16	In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	10
17	Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian) Tj ETQq1 1 0.784314 rgBT /Overlock 10 25, 346-350.	0.9	7
18	Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017. Antimicrobial Agents and Chemotherapy, 2021, 65, e0200020.	1.4	61

#	Article	IF	Citations
19	In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin. Jammi, 2021, 6, 149-162.	0.3	0
20	Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-7.	0.7	3
21	In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115418.	0.8	8
22	Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007â€“2018. Vaccine, 2021, 39, 5474-5483.	1.7	6
23	Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. Journal of Clinical Microbiology, 2021, 59, e0163521.	1.8	7
24	Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011â€“2018. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115447.	0.8	7
25	In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017â€“2019. Brazilian Journal of Infectious Diseases, 2021, 25, 101647.	0.3	10
26	In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015â€“2017. Journal of Global Antimicrobial Resistance, 2020, 21, 223-228.	0.9	37
27	In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum Î²-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagnostic Microbiology and Infectious Disease, 2020, 96, 114925.	0.8	25
28	In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	50
29	Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing Escherichia coli clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007â€“2017). Diagnostic Microbiology and Infectious Disease, 2020, 96, 114962.	0.8	2
30	In-vitro activity of imipenem/relebactam and key Î²-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients â€“ SMART Surveillance United States 2015â€“2017. International Journal of Antimicrobial Agents, 2020, 55, 105841.	1.1	26
31	Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2. Journal of Virological Methods, 2020, 285, 113970.	1.0	24
32	Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant Escherichia coli Clinical Isolates from Canadian Hospitals. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	9
33	Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four In Vitro Testing Methods. Journal of Clinical Microbiology, 2020, 58, .	1.8	8
34	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs, 2020, 80, 285-313.	4.9	60
35	In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. Diagnostic Microbiology and Infectious Disease, 2020, 97, 115012.	0.8	36
36	Cefotaxime susceptibility should not be used to predict ceftriaxone susceptibility among Klebsiella oxytoca clinical isolates. Journal of Global Antimicrobial Resistance, 2020, 21, 270-271.	0.9	1

#	Article	IF	Citations
37	Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017. Journal of Antimicrobial Chemotherapy, 2020, 75, 1824-1832.	1.3	15
38	In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	9
39	Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020, 2020, 1-11.	0.7	12
40	In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples â€“ SMART Surveillance Europe 2015â€“2017. Journal of Medical Microbiology, 2020, 69, 207-217.	0.7	43
41	Microbiology and Preclinical Review of Omadacycline. Clinical Infectious Diseases, 2019, 69, S6-S15.	2.9	55
42	Characterization of MRSA in Canada from 2007 to 2016. Journal of Antimicrobial Chemotherapy, 2019, 74, iv55-iv63.	1.3	19
43	Clinical utility of echocardiography for the diagnosis of native valve infective endocarditis in Staphylococcus aureus bacteremia. Echocardiography, 2019, 36, 1852-1858.	0.3	4
44	Answer to November 2019 Photo Quiz. Journal of Clinical Microbiology, 2019, 57, .	1.8	0
45	Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007â€“16 study. Journal of Antimicrobial Chemotherapy, 2019, 74, iv32-iv38.	1.3	23
46	Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011â€“16 study. Journal of Antimicrobial Chemotherapy, 2019, 74, iv48-iv54.	1.3	27
47	Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016. Journal of Antimicrobial Chemotherapy, 2019, 74, iv64-iv71.	1.3	36
48	Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007â€“16. Journal of Antimicrobial Chemotherapy, 2019, 74, iv39-iv47.	1.3	21
49	42936 pathogens from Canadian hospitals: 10 years of results (2007â€“16) from the CANWARD surveillance study. Journal of Antimicrobial Chemotherapy, 2019, 74, iv5-iv21.	1.3	43
50	Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013â€“2017). Diagnostic Microbiology and Infectious Disease, 2019, 94, 199-201.	0.8	4
51	CHROMagarâ„¢ orientation urine culture medium produces matrix-assisted laser desorption ionizationâ€“time-of-flight mass spectrometry spectra misidentified as Mycoplasma arginini and Mycoplasma alkalescens. Diagnostic Microbiology and Infectious Disease, 2019, 94, 113-115.	0.8	5
52	Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States â€” SMART 2015â€“2017. Diagnostic Microbiology and Infectious Disease, 2019, 95, 212-215.	0.8	21
53	Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015â€“17. Journal of Antimicrobial Chemotherapy, 2019, 74, 2284-2288.	1.3	34
54	In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007â€“2016. International Journal of Antimicrobial Agents, 2019, 54, 62-68.	1.1	14

#	Article	IF	Citations
55	Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagnostic Microbiology and Infectious Disease, 2019, 94, 321-325.	0.8	57
56	Report of a KPC-producing Pseudomonas aeruginosa isolate in Canada. Journal of Antimicrobial Chemotherapy, 2019, 74, 1748-1749.	1.3	4
57	Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. Journal of Antimicrobial Chemotherapy, 2019, 74, 645-653.	1.3	26
58	In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	20
59	In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. International Journal of Antimicrobial Agents, 2019, 53, 456-466.	1.1	119
60	In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
61	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs, 2019, 79, 271-289.	4.9	274
62	Photo Quiz: A 59-Year-Old Male with Nodular Cutaneous Lesions. Journal of Clinical Microbiology, 2019, 57, .	1.8	0
63	PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium icile Surveillance Study (CAN-DIFF) 2013â€“2015. Diagnostic Microbiology and Infectious Disease, 2018, 91, 105-111.	0.8	23
64	In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. Journal of Antimicrobial Chemotherapy, 2018, 73, 1872-1879.	1.3	68
65	Analysis of Potential Î²-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae. Journal of Clinical Microbiology, 2018, 56, .	1.8	3
66	In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014â€“2015. Diagnostic Microbiology and Infectious Disease, 2018, 91, 55-62.	0.8	60
67	In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008â€“16. Journal of Antimicrobial Chemotherapy, 2018, 73, 703-708.	1.3	21
68	In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	102
69	Imipenemâ€“Relebactam and Meropenemâ€“Vaborbactam: Two Novel Carbapenem-Î²-Lactamase Inhibitor Combinations. Drugs, 2018, 78, 65-98.	4.9	291
70	In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	187
71	2383. In Vitro Activity of Ceftolozaneâ€“Tazobactam in Comparison With Ceftazidimeâ€“Avibactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007â€“2017. Open Forum Infectious Diseases, 2018, 5, S710-S710.	0.4	0
72	Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015â€“2016. Journal of Global Antimicrobial Resistance, 2018, 15, 140-147.	0.9	39

#	Article	IF	Citations
73	Failure of a multiplex polymerase chain reaction assay to detect IMP-27 in a clinical isolate of Morganella morganii. Diagnostic Microbiology and Infectious Disease, 2018, 92, 194-195.	0.8	2
74	Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli. Canadian Journal of Infectious Diseases and Medical Microbiology, 2018, 2018, 1-9.	0.7	26
75	Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology, 2018, 2018, 1-13.	0.7	31
76	Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011â€“15. Journal of Antimicrobial Chemotherapy, 2018, 73, vii12-vii19.	1.3	48
77	Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011â€“15. Journal of Antimicrobial Chemotherapy, 2018, 73, vii20-vii31.	1.3	27
78	Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011â€“15. Journal of Antimicrobial Chemotherapy, 2018, 73, vii5-vii11.	1.3	17
79	Evaluation of three <scp>MALDI</scp>â€<scp>TOF</scp> mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada. Mycoses, 2018, 61, 743-753.	1.8	50
80	In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. Diagnostic Microbiology and Infectious Disease, 2017, 87, 349-356.	0.8	10
81	Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013â€“2015. Brazilian Journal of Infectious Diseases, 2017, 21, 343-348.	0.3	41
82	Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model. Diagnostic Microbiology and Infectious Disease, 2017, 88, 271-275.	0.8	6
83	In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study). Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	159
84	In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	129
85	In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	127
86	In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014. Journal of Clinical Microbiology, 2017, 55, 1638-1649.	1.8	77
87	In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 â€“ Results from the SMART global surveillance program. Diagnostic Microbiology and Infectious Disease, 2017, 88, 171-176.	0.8	39
88	Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide. Journal of Clinical Microbiology, 2017, 55, 3021-3027.	1.8	7
89	In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016. Diagnostic Microbiology and Infectious Disease, 2017, 89, 151-157.	0.8	15
90	Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008â€“2015. Diagnostic Microbiology and Infectious Disease, 2017, 87, 60-63.	0.8	36

#	Article	IF	Citations
91	In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 Stenotrophomonas maltophilia Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011â€“2016). Open Forum Infectious Diseases, 2017, 4, S367-S368.	0.4	0
92	In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008â€“2016. Open Forum Infectious Diseases, 2017, 4, S372-S372.	0.4	0
93	Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asiaâ€“Pacific countries: SMART 2013â€“2015. Journal of Medical Microbiology, 2017, 66, 61-69.	0.7	53
94	Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-10.	0.7	58
95	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2016, 76, 1737-1757.	4.9	38
96	Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). CMAJ Open, 2016, 4, E641-E645.	1.1	24
97	In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 4743-4749.	1.4	132
98	Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity. MBio, 2016, 7, e00169.	1.8	3
99	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs, 2016, 76, 567-588.	4.9	199
100	Fidaxomicin: A Novel Agent for the Treatment ofClostridium difficileInfection. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 305-312.	0.7	59
101	Empyema Caused byClostridium bifermentans: A Case Report. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 105-107.	0.7	23
102	In Vitro Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals. Antimicrobial Agents and Chemotherapy, 2015, 59, 3623-3626.	1.4	10
103	Isolation of multiple carbapenemase-producing Gram-negative bacilli from a patient recently hospitalized in Nigeria. Diagnostic Microbiology and Infectious Disease, 2015, 81, 296-298.	0.8	19
104	Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007â€“13. Journal of Antimicrobial Chemotherapy, 2015, 70, 2199-2202.	1.3	65
105	Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance. Clinical Infectious Diseases, 2015, 61, S58-S68.	2.9	71
106	Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistantStreptococcus pneumoniae: analysis of Phase 3 clinical trial dataâ€”authors' response: Figure 1.. Journal of Antimicrobial Chemotherapy, 2015, 70, 3170.2-3171.	1.3	5
107	Evaluation of Five Chromogenic Agar Media and the Rosco Rapid Carb Screen Kit for Detection and Confirmation of Carbapenemase Production in Gram-Negative Bacilli. Journal of Clinical Microbiology, 2015, 53, 105-112.	1.8	38
108	An Unusual Case ofStreptococcus anginosusGroup Pyomyositis Diagnosed Using Direct 16S Ribosomal DNA Sequencing. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 32-34.	0.7	8

#	Article	IF	Citations
109	Osteomyelitis Due to Multiple Carbapenemase-Producing Gram-Negative Bacteria: The First Case Report of a GES-13-ProducingPseudomonas aeruginosaIsolate in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 229-231.	0.7	9
110	254In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013. Open Forum Infectious Diseases, 2014, 1, S109-S109.	0.4	0
111	In VitroActivity of Fosfomycin against Escherichia coli Isolated from Patients with Urinary Tract Infections in Canada as Part of the CANWARD Surveillance Study. Antimicrobial Agents and Chemotherapy, 2014, 58, 1252-1256.	1.4	42
112	Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data. Journal of Antimicrobial Chemotherapy, 2014, 69, 2835-2840.	1.3	25
113	Molecular epidemiology of extended-spectrum Â-lactamase-, AmpC Â-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. Journal of Antimicrobial Chemotherapy, 2013, 68, i57-i65.	1.3	131
114	Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. Journal of Antimicrobial Chemotherapy, 2013, 68, i7-i22.	1.3	114
115	Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. Journal of Antimicrobial Chemotherapy, 2013, 68, i47-i55.	1.3	40
116	Evaluation of MRSASelect^{â„¢}Chromogenic Medium for the Early Detection of Methicillin-ResistantStaphylococcus aureusfrom Blood Cultures. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, e113-e116.	0.7	6
117	Prevalence of Antimicrobial Resistance among Clinical Isolates of Bacteroides fragilis Group in Canada in 2010-2011: CANWARD Surveillance Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 1247-1252.	1.4	89
118	In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007â€“2009 study. Diagnostic Microbiology and Infectious Disease, 2011, 69, 342-347.	0.8	31
119	Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance Study. Antimicrobial Agents and Chemotherapy, 2011, 55, 3169-3175.	1.4	97
120	Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrobial Agents and Chemotherapy, 2010, 54, 4684-4693.	1.4	138
121	Analysis of 1560 Inpatient and OutpatientEscherichia coliIsolates from across Canadaâ€”Results from the CANWARD 2007 Study. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, 49A-53A.	0.7	2
122	AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity. Antimicrobial Agents and Chemotherapy, 2009, 53, 3544-3548.	1.4	71
123	Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. International Journal of Antimicrobial Agents, 2009, 34, 375-379.	1.1	29
124	Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006. Antimicrobial Agents and Chemotherapy, 2008, 52, 1430-1437.	1.4	207
125	In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. International Journal of Antimicrobial Agents, 2006, 27, 174-177.	1.1	34
126	Review of Macrolides and Ketolides. Drugs, 2001, 61, 443-498.	4.9	249

#	Article	IF	Citations
127	A Canadian National Surveillance Study of Urinary Tract Isolates from Outpatients: Comparison of the Activities of Trimethoprim-Sulfamethoxazole, Ampicillin, Mecillinam, Nitrofurantoin, and Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2000, 44, 1089-1092.	1.4	148
128	Prevalence of Antimicrobial Resistance in Respiratory Tract Isolates of Streptococcus pneumoniae : Results of a Canadian National Surveillance Study. Antimicrobial Agents and Chemotherapy, 1999, 43, 2504-2509.	1.4	88
129	Ciprofloxacin or Imipenem Use Correlates with Resistance inPseudomonas aeruginosa. Canadian Journal of Infectious Diseases & Medical Microbiology, 1998, 9, 382-386.	0.3	4
130	Screening of Stool Samples for Identification of Vancomycin-Resistant Enterococcus Isolates Should Include the Methyl-Î±- d Glucopyranoside Test To Differentiate Nonmotile Enterococcus gallinarum from E. faecium. Journal of Clinical Microbiology, 1998, 36, 2333-2335.	1.8	27